Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

References

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Leukemia doi:10.1038/leu.2012.134

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).
J Clin Oncol 30, 2012 (suppl; abstr 6509^)

Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.
J Clin Oncol 30, 2012 (suppl; abstr 6505^)

Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.
J Clin Oncol 30, 2012 (suppl; abstr 6504)

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
J Clin Oncol 30, 2012 (suppl; abstr 6503)

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings
ASH Annual Meeting
2011; Presentation #210

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
J Clin Oncol (Meeting Abstracts)
May 2011 vol. 29 no. 15_suppl 6511

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial
ASH Annual Meeting
2011; Presentation #2767

Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION
J Clin Oncol (Meeting Abstracts)
May 2011 vol. 29 no. 15_suppl 6510

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up
ASH Annual Meeting
2011; Presentation #206

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
ASH Annual Meeting
2011; Presentation #207

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
The Lancet Oncology; Volume 12, Issue 9
, September 2011, Pages 841–851

Updated Phase 1 Data on Ponatinib, a Pan-BCR-ABL Inhibitor, in CML and Other Hematologic Malignancies
ESH-iCMLf 13th International Conference
, September 2011

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies
ASH Annual Meeting 2011; Presentation #602

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings
Blood (ASH Annual Meeting Abstracts)
2010 116: Abstract 210

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 6

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
J Clin Oncol (Meeting Abstracts)
May 2010 vol. 28 no. 15_suppl 6501

Continued Superiority of Nilotinib vs Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond 1 Year
Haematologica
2010; 95[suppl.2]:459, abs. 1113

Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
J Clin Oncol (Meeting Abstracts)
June 2010 vol. 28 no. 18_suppl LBA6500

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
N Engl J Med
2010; 362:2260-2270

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
N Engl J Med
2010; 362:2251-2259

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes